EGAGenomicsCancer Genomicshttps://ega-archive.org/studies/EGAS00001007292EGAEGA study EGAS00001007292Tagged-amplicon deep sequencingShallow whole genome sequencingrestrictedEGAserous cystadenocarcinoma, grade 3/4, study., NOS (morphologic abnormality), serous carcinoma, high gradeTherapy, Relapse, Antemortem Diagnoses, screening, Antemortem Diagnosis, findings, chemotherapy, number, Great Britain, Genome Sequencing, pharmacotherapy, Platin, Pharmacotherapies, short., Diagnosis, Client, presence, Examination and Diagnoses, Diagnoses, Chemotherapies, shortened, Pt, count in organism, relapse, low depth, Isle of Man, Postmortem, Screenings, Complete Genome, Recrudescence, Mass Screenings, Examinations and Diagnoses, Mass, symptoms, Screening, Chemotherapy, Relapses, Antemortem, Postmortem Diagnosis, Drug Therapies, Diagnoses and Examination, study, platine, Postmortem Diagnoses, Complete, Whole Genome, Pharmacotherapy, NOS (morphologic abnormality), platino, Recrudescences, Recurrences, Complete Genome Sequencing, signs, stubby, Diagnoses and Examinations, U.K., serous carcinoma, 78Pt, Sequencing, paired, serous cystadenocarcinoma, Drug, Platinum Black, Patient, Clients, Whole, cardinality, Therapies, pharmacologic therapy, shallow, DiagnosefalseThe genomic landscape of recurrent ovarian high grade serous carcinoma: the BriTROC-1 studyThe BriTROC-1 study, spanning 15 centres across the United Kingdom, is a prospective observational project investigating putative causes of relapse in high-grade serous carcinoma (HGSC). Potential genomic changes associated with disease recurrence are examined by studying paired tumour samples collected from patients at diagnosis and after relapse after receiving platinum based chemotherapy. Shallow whole genome sequencing and targeted amplicon sequencing are used to identify copy number aberrations and short variants respectively.2023-08-23 09:10:03EGAS000010072929606EGAD00001011049EGAD00001011058EGAC00001000388